I now turn to El Fabrio. Last year, our commercial partner, Chiesi Global Rare Diseases, continued to increase its focus on Ophabolio and invest substantially in medical and commercial programs.

New initiative aims to accelerate diagnosis and ease NHS pressures Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC) have launched COMET, a programme designed to enhance early ...

Krystal reported $250.5 million in sales for Vyjuvek in 2024. The FDA in 2023 also approved Chiesi Group’s Filsuvez, a topical gel whose main pharmaceutical ingredient is intended to promote ...

VYVGART could be the first CIDP drug with a novel mechanism in 30 years Argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) ...

aResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias, Santa Cruz de Tenerife, Spain bGenomics Division, Instituto Tecnológico y de ...

Copyright: © 2024 The Author(s). Published by Elsevier Ltd.